Asymptomatic Bacteriuria with *Escherichia coli* in Type 2 Diabetic Patients: An Unresolved Riddle

Archana Deraje¹, Shalini Shenoy², B. Dhanshree² and Prabha Adhikari¹*

¹Department of Internal Medicine, Kasturba Medical College, Manipal University, India.
²Department of Microbiology, Kasturba medical College, Manipal University, India.

**Authors’ contributions**

This work was carried out in collaboration between all authors. Author AD designed the study, wrote the protocol and wrote the first draft of the manuscript. Authors SS, BD and PA managed the literature searches and reviewed the manuscript. All authors read and approved the final manuscript.

**Article Information**

DOI: 10.9734/BJMMR/2016/20800

(1) Pasquapina Ciarmela, Department of Experimental and Clinical Medicine, Polytechnic University of Marche, Italy.

(1) Akobi Oliver Adeyemi, Federal Medical Centre, Bida, Niger State, Nigeria.

(2) Ilham Zahir, University Sidi Mohamed Ben Abdellah, Morocco.

(3) Rubina Naqvi, Sindh Institute of Urology and Transplantation, Karachi, Pakistan.

Complete Peer review History: [http://sciencedomain.org/review-history/11497](http://sciencedomain.org/review-history/11497)

Received 9th August 2015
Accepted 1st September 2015
Published 22nd September 2015

**ABSTRACT**

Asymptomatic bacteriuria (ASB) is a common finding, but there is a considerable controversy about the appropriate management of bacteriuria. ASB was found to be three times higher in patients with diabetes, especially in women when compared to non-diabetic counterpart. Asymptomatic bacteriuria is the presence of bacteria in the urine presenting without any clinical symptoms of UTI. The objective of this review is to highlight the studies done on ASB in diabetes patients with special reference to *Escherichia coli* (*E. coli*), risk factors and its management. The review showed that increasing age, females, post-menopausal status, poor glycaemic control, long duration of diabetes, microalbuminuria, leukocyturia, poor hygiene were associated with ASB. Available literature does not support the use of antibiotics, however short term trials have shown benefit with topical esteriol. Further clinical trials are needed.

**Keywords:** Asymptomatic bacteriuria; *E. coli*; type 2 diabetes mellitus; risk factor; management.
1. INTRODUCTION

An estimated 150 million Urinary tract infection occurs annually worldwide [1]. It is known that diabetes increases the risk of infection especially that of genitourinary tract. Both symptomatic and asymptomatic urinary tract infections are reported to occur with increased frequency in patients with type 2 diabetes especially in women. A study has shown that ASB may lead to symptomatic urinary infection, as well as increase in the frequency of renal failure as one of the long term adverse effects [2]. Asymptomatic bacteriuria is the presence of bacteria in the bladder urine presenting without any clinical symptoms of UTI [2]. Studies have shown that age, sexual activities, duration of diabetes, metabolic control of the disease and the state of complications are known to be the predisposing factor for the development of ASB in diabetics [3,4,5]. ASB is usually caused by normal flora of the gut, which then ascends up the urethra into the bladder and potentially the kidneys [6]. Changes in the host defence mechanisms, presence of diabetic cystopathy and microvascular disease in kidney may play a role which increases the incidence of UTI in diabetic patients [7]. Several studies have shown Escherichia coli as the most common causative agent of UTI in both diabetic and non-diabetic patients, uropathogenic E. coli possesses variety of pathogenicity determinants that make colonization of Urinary tract possible [8,9,10].

This review aims to determine the best available evidence from original articles and randomised trials.

2. METHODOLOGY

2.1 Literature Survey

A literature search of Medline, PubMed was done using the term “Asymptomatic bacteriuria in diabetes mellitus” for the years 1986 to 2014 in order to find all the articles that considered epidemiology, risk factors, prognosis of ASB in patients with type 2 diabetes. On the basis of title and displayed abstract, articles were chosen for the selected topics. A total of 143 articles were found. Only studies in which ASB was defined as absence of symptoms of UTI and isolation of at least 10^5 CFU/ml of the same bacteria in two consecutive urine cultures were included. Among the non-english articles, only those with abstract in english were reviewed and included. Of the published articles 47 original articles, 19 reviewed and 5 clinical articles were excluded in which studies were mainly focused on symptomatic UTI and type 1 diabetes mellitus.

2.2 Outcome Measures

Data on prevalence, risk factors, intervention used and efficacy of intervention were collected.

143 articles were identified

62 articles excluded (Studies on symptomatic UTI / were not written in english)

19 original articles (ASB)

32 review articles 21 articles (mention of ASB)

09 clinical trials
### Table 1. Summary of characteristic finding of original articles (cross-sectional and cohort studies)

| Year | Study site | Total no of patients / Total no of patients with type 2 DM | Prevalence of ASB among DM | Risk factor | Antimicrobial pattern | Treatment |
|------|------------|----------------------------------------------------------|----------------------------|-------------|-----------------------|-----------|
| 2013; Cameroon [11] | 265/154 | 38.3% | Diabetes mellitus | Ciprofloxacin was most effective | Not recommended |
| 2013; Moscow [12] | 414/414 | 22.7% | Post menopausal | Na | Usage of local form of esterol |
| 2012; Ethiopia [13] | 413/306 | 10.4% | Female | S-Aminoglycosides, Qinolones, Cephalosporins | Recommended |
| 2008; Nigeria [14] | 192/135 | 16% | Diabetes old age poor glycaemic control | S-Nitrofurans | Follow up recommended |
| 2007; Iran [15] | 100/100 | 72.3% | Uncontrolled diabetes | S-Aminoglycosides | NA |
| 2006; Pisa [16] | 1321/346 | 12.76%-M 14.97%-F | Old age female | Multidrug resistant | NA |
| 2005; Australia [17] | 496/496 | 7.3% | Female | S-Aminoglycosides | Not recommended |
| 2003; Spain [19] | 289/289 | 25.6% | Increased levels of CRP, microalbuminuria leukocyturia, | S- Cephalosporins | Vaginal topical estrogen was effective |
| 2002; Chile [21] | 100/50 | 32% | Leukocyturia, longer duration of DM | NA | NA |
| 2002; Zimbabwe [22] | 176/Na | 32% | Glucosuria, leukocyturia | S- Quinolones | Continuous surveillance in hospital and community |
| 2001; Italy [23] | 148/Na | 46.62% | Hygiene | S- Aminoglycosides | Careful hygiene habits recommended |
| 1998; Cuba [24] | 735/Na | 8% | DM, old age, female | NA | Urine culture in case of leukocyturia |
| 1997; Netherlands [25] | 63/63 | 32% | Female | S- Augmentin, Quinolones, Gentamycin | Recommended |
| 1996; Kenya [26] | 135/135 | 11% | NA | NA | Not recommended |
| 1998; Colorado [27] | 624/206 | 5.8% | Old age, duration of DM | NA | NA |
| 1996; Nigeria [28] | 380/190 | 6.3% | Female, old age | NA | NA |
| 1996; California [29] | 341/341 | 9% | Female, duration of DM | NA | NA |

Note: Na: Not available; DM: Diabetes mellitus; M: Male; F: Female; S: Sensitive; R: Resistance; Multidrug resistant: Resistant to quinolones and Cephalosporins
Table 2. Summary of characteristics of findings of clinical trials (observational and clinical trials)

| Year     | Study site          | Patients profile case / control | Intervention                                                                 | Results                                                                 | Conclusion                                      |
|----------|---------------------|---------------------------------|------------------------------------------------------------------------------|------------------------------------------------------------------------|------------------------------------------------|
| 2013     | Moscow [37]         | 87, Follow up- 12 months        | Group 1- treated with esteriol group 2- No therapy                           | Group 1- ASB in 19.4% Group 2 – ASB in 68.4%                            | Esteriol prevents UTI in postmenopausal women   |
| 2009     | Canada [38]         | 70, Follow up- 3 months to 3 years | 36 women – treated 34 women - Not treated                                    | ASB- 36% Antibiotic group 76% had recurrent infection                  | Treatment does not resolve ASB                 |
| 2006     | Spain [39]          | 457, Follow up- 12 months       | NA                                                                           | With ASB- 67.6% women Without ASB- 14.9% women                         | Treatment not recommended                      |
| 2006     | Canada [40]         | 50 Type 1 DM-9 Type 2 DM-41 Follow up- 36 months | 50- Placebo. Antibiotics after 3 months for symptomatic UTI            | Persistent ASB at year 1.2 and 3 36%, 23%, 23%                         | Urine culture not recommended                  |
| 2004     | Netherlands [41]    | 229                             | NA                                                                           | ASB- 19%                                                               | Treatment not recommended                      |
| 2004     | Seattle [42]        | 218-DM 799-Non DM 2 years follow-up | NA                                                                           | ASB with DM- 10.6% ASB without DM- 5.5%                                 | ASB is considered complication in postmenopausal women. |
| 2002     | Canada [43]         | 50-placebo 55-treated 36 months follow up | Treatment- Co, orally twice a day                                          | Therapy - 66 episodes of ASB Placebo 23 episodes of ASB                | Treatment not recommended                      |
| 2001     | Netherlands [44]    | 258-type 1                      | NA                                                                           | ASB in type 1-21% ASB in type 2- 29% Control -6%                        | ASB is considered complication of diabetes in women. |
| 1995     | Canada [45]         | Type 1- 264 Type 2 - 676        | NA                                                                           | ASB- 7.9% (85) out of 85, ASB in type 2- 75.3%, type 1- 22.4%           | Origin and duration of diabetes increases ASB   |

Note: NA: Not available; DM: Diabetes mellitus; Co: Cotrimaxozole
2.3 Epidemiology

From the literature survey the prevalence of ASB is higher in diabetic patients especially in diabetic women, in whom it is three times higher when compared to non-diabetics [8]. Studies from different countries like USA, Canada, Australia, Cuba, Moscow, Italy and many Asian and African countries have shown 5.8% to 53% diabetic patients have ASB [11-29]. The most common aetiological agents causing ASB is found to be *Escherichia coli* (*E. coli*) followed by *Klebsiella* specie, *Proteus* specie, *Pseudomonas* specie, *Enterobacter* specie and gram positive organisms include *Staphylococcus aureus*, group B *Streptococcus*, *Enterococcus* specie [30]. However there are some studies which report *Klebsiella* specie as the common organism isolated [31,32,33]. One of the factor for the increase pathogenicity of uropathogenic *E. coli* is adhesins which promote attachment to the human urogenital tract causing inflammatory response [34].

2.4 Findings

There are very limited numbers of molecular studies especially on asymptomatic bacteriuria in diabetes. Geerling et al. [35] showed that type 1 fimbriae is the most prevalent virulence factor of *E. coli* isolated from urine of diabetic women with ASB. These studies also found an association of decline in renal function and presence of *E. coli* that can code for Cnf or Sfa or express type 1 fimbriae. An animal study by Mizunoe et al. [36], showed that *E. coli* with type 1 fimbriae caused severe scarring, whereas strains without type 1 or with pfimbriae did not. Table 1 shows the prevalence, risk factors, antimicrobial profile and recommendations of the original articles. Table 2 shows the observations, interventions, results and conclusion of various clinical trials which were referred in preparing this article.

3. Risk Factors Associated with ASB

Several studies have shown many factors associated with ASB.

3.1 Age as Risk Factor

Elderly population both male and female have higher prevalence of ASB [46,47]. Dementia generally seen in elderly may be associated with ASB because the affected patients may be unable to recognise symptoms or not able to report symptoms. ASB is also prevalent in elderly long term care residents who are prone to cognitive deficits which may be considered as a risk factor. Poor hygiene and incomplete bladder emptying can also be a potential contributor for ASB [48].

3.2 Gender as Risk Factor

It is evident from the various observational and cross-sectional studies; females are more prone to urinary tract infection both symptomatic and asymptomatic, which is attributed due to short urethra that is in proximity to the areas that are colonised with enteric bacteria [49,13,17]. Geerlings et al. [31] found that prevalence of ASB is higher in women with diabetes mellitus than in women without diabetes: (26% versus 6%). Increased frequency of ASB is seen in postmenopausal women due to significant atrophic changes of the vaginal mucosa and urethra with estrogen deficiency and changes of the vaginal flora leading to high pH and low VHI (vaginal health index) [37]. Studies have also shown that sexually active female can also develop ASB [43].

3.3 Glycosuria, Macroalbumunuria, Glycated Haemoglobin (HbA1c) and Pyuria as Risk Factor

Glycosuria, macroalbumunuria and pyuria was considered as a risk factor for ASB [50,51]. The presence of pyuria in cases of ASB has shown not to be significant however some studies show that presence of pyuria in ASB can be a risk factor for developing symptomatic UTI. Nakano et al. [50] suggest that asymptomatic pyuria is more prevalent in diabetic women than in non-diabetic women: (27% vs 15.8%). The findings of their study indicate degree of neuropathy, nephropathy and retinopathy increases the prevalence of asymptomatic pyuria in women with type 2 diabetes. Papazafiropolou et al. [51] suggest that diabetic subjects with macroalbuminuria showed increased prevalence of ASB compared to diabetic subjects without macroalbuminuria which has showed to be statistically significant with p<0.001. The presence of macroalbuminuria has shown to be a marker for endothelial dysfunction leading to structural damages to the kidneys, which in turn makes them susceptible for bacterial colonization resulting in an elevated risk for developing ASB. Kasian et al. [37] and collaborators found no correlation between ASB
and glycosylated haemoglobin A1C whereas Aswani et al. [52] and associates suggest that increased A1C predisposes diabetics to UTI [46]. Hale Turan et al. [20] showed significant association of A1C and ASB. Their findings also suggest that high level of A1c in diabetic patients can be defined as a risk factor for ASB. A possible explanation for this could be likely that hyperglycaemia may impair the host defence response to microorganisms by affecting the polymorphonuclear leukocyte functions [53,54]. But their significance has not yet been confirmed through clinical studies. However, other studies found no correlation between glycaemic controls and ASB. Geerlings et al. [31] and Hale Turan et al. [20] found significant association between duration of diabetes and ASB, it was considered as a predisposing risk factor. Moreover a trial study showed that the risk factor for the development of symptomatic UTI in women with type 2 diabetes was the presence of ASB [37].

4. MANAGEMENT OF ASB

There has been considerable controversy about the appropriate management of bacteriuria and especially ASB in diabetic patients. The necessity to treat or not to treat ASB in type 2 diabetic patients is matter of controversy, as per IDSA (Infectious diseases Society of America) guidelines, treatment of ASB is recommended only for pregnant women or for those undergoing invasive genitourinary procedures [55]. Several studies have been done in the past to assess whether treatment is required in management of ASB. Although it is recommended that ASB need not be treated, we see high prevalence of E. coli sepsis in diabetes patients leading to high mortality [56], treating becomes mandatory when develop active infection for such patients. Papazafiropolou et al. [51] suggests that bacteriological screening of ASB is warranted in diabetic patients especially if pyuria is detected in urine analysis. There is a current opinion that prescription of antibiotics to diabetic patients with ASB is necessary only to those patients who need catheterization or have urinary tract structural abnormalities [48]. Antimicrobial therapy clears bacteriuria in short term, but does not decrease the number of symptomatic episode and hospitalization during long-term follow up [38]. Large number of studies shows that an antimicrobial treatment in ASB does not lead to decreasing of frequency of recurrences and re-infection [11,18,22]. Treatment of ASB in women with diabetes does not appear to reduce complication and that screening and treatment are not needed [38]. In case of postmenopausal diabetic women with ASB the local forms of estriol are found to be effective [57,12,37], safety needs to be established for long term use. In a one year study Cranberry juice was shown to reduce incidence of bacteriuria, however longer trial are needed to confirm their efficacy [58]. This literature reviewed, does not support the antibiotic use for ASB in diabetic patients, however these patients are at high risk of developing urinary tract infection and hence they need to be actively monitored for sign and symptoms of urinary tract infection and early antibiotic use is recommended if they become symptomatic.

5. CONCLUSION

Asymptomatic bacteriuria is common in diabetic patients especially in women and elderly population. This review shows that poor glycaemic control, macroalbuminuria, pyuria, longer duration of diabetes and hygiene can be considered as the risk factor for developing ASB. In most of the developing countries, where health related spending is a major limiting factor to access better healthcare, it is important that a physician in the primary healthcare setup to have a certain level of awareness with regard to diagnosis, prevention and treatment of ASB in the high risk group.

CONSENT

It is not applicable.

ETHICAL APPROVAL

It is not applicable.

ACKNOWLEDGEMENT

Authors acknowledge Manipal University, Head of Institution, Kasturba Medical College, for continuous support and encouragement.

COMPETING INTERESTS

Authors have declared that no competing interests exist.

REFERENCES

1. Ferrieres L, Hancock V, Klemm P. Biofilm exclusion of uropathogenic bacteria by selected asymptomatic bacteriuria
Escherichia coli strains. Microbiology. 2007;153:1711-1719.

2. BD Sharma, Rohit Bansal, B Gupta. Asymptomatic bacteriuria in diabetics. JIACM. 2011;13(1):55-59.

3. Sawer JS, Todd A, Kellett HA, et al. Bacteriuria and autonomic nerve function in diabetic women. Diabet Care. 1986;9:460-464.

4. Schmitt JK, Fawcett CJ, Gullickson G. Asymptomatic bacteriuria and hemoglobin A1. Diabetes Care. 1986;9(5):518-20.

5. Harding GK, Zhanel GG, Nicolle LE, Cheang. Antimicrobial treatment in diabetic women with asymptomatic bacteriuria. Manitoba diabetes urinary tract infection study group. N Engl J Med. 2002;347(20):1576-83.

6. Ariathianto Y. Asymptomatic bacteriuria - prevalence in the elderly population. Aust Fam Physician. 2011;40(10):805-9.

7. Sridhar CB, Anjana S, Mathew JT. Acute Infections. RSSDI Text book of diabetes mellitus edited by- Ahuja MMS, Tripathy BB, Sam Moses GP, Chandalia HB, Das AK, Rao P.V Hyderabad, India. 2002; Chap: 34:471-8.

8. Ruby Meiland, Suzanne.E, Geerlings, Ronald P, Patrick M, Peter M, Andy. I. M. Hopelman. Asymptomatic bacteriuria in women with diabetes. Arch Intern Medicine. 2006;166(20)2222-2227.

9. Renko M, Tapanainen P, Tossavainen P, Pokka T, Uhari M. Meta-analysis of the significance of asymptomatic bacteriuria in diabetes. Diabetes Care. 2011;34(1):230-5.

10. Janifer J, Geethalakshmi S, Satyavani K, Vishwanthan V. Prevalence of lower UTI in South Indian type 2 diabetic subjects. Ind J of Nephro. 2009;19:3:107-111

11. Bissong ME, Fon PN, Tabes-Bissong FO, Akenji TN. Asymptomatic bacteriuria in diabetes mellitus patients in Southwest Cameroon. Afr Health Sci. 2013;13(3):661-6.

12. Kasyan G, Berketova TY, Rogozin AK, Pushkary D. Asymptomatic bacteriuria in postmenopausal women with diabetes mellitus. Cent European J Urol. 2013;66(3):320-6.

13. Yeshtela B, Gebre-Selassie S, Feleke Y. Asymptomatic bacteriuria and symptomatic urinary tract infections (UTI) in patients with diabetes mellitus in Tikur Anbessa Specialized University Hospital, Addis Ababa, Ethiopia. Ethiop Med J. 2012;50(3):239-49.

14. Odetoyn WB, Aboderin AO, Ikem RT, Kolawole BA, Oyelese AO. Asymptomatic bacteriuria in patients with diabetes mellitus in Ile-Ife, South-West, Nigeria. East Afr Med J. 2008;85(1):18-23.

15. Hassanzadeh P, Motamedifar M. The prevalence of asymptomatic bacteriuria in long term care facility residents in Shiraz, Southwest Iran: A cross-sectional study. Pak J Biol Sci. 2007;10(21):3890-4.

16. Bonadio M, Costarelli S, Morelli G, Tartaglia T. The influence of diabetes mellitus on the spectrum of uropathogens and the antimicrobial resistance in elderly adult patients with urinary tract infection. BMC Infect Dis. 2006;17(6):54.

17. Karunajeewa E, McGeachie D, Stuccio G, Stingemore N, Davis WA, Davis TM. Asymptomatic bacteriuria as a predictor of subsequent hospitalisation with urinary tract infection in diabetic adults: The Fremantle Diabetes Study. Diabetologia. 2005;48(7):1288-91.

18. Hermida Pérez JA, Loro Ferrer JF. Asymptomatic bacteriuria in women. Epidemiological, pathologic and therapeutic study. Arch Esp Urol. 2004;57(8):784-804.

19. Ribera Montés Mdel C, Pérez RP, Barba CP, Beltrán DO, Carbonell VP. Risk factors for asymptomatic bacteriuria in women with diabetes. Clin Infect Dis. 2004;39(11):1732-3.

20. Turan H, Serefhanoglu K, Torun AN, Kulaksizoglu S, Kulaksizoglu M, Pamuk B, et al. Frequency, risk factors, and responsible pathogenic microorganisms of asymptomatic bacteriuria in patients with type 2 diabetes mellitus. Jpn J Infect Dis. 2008;61(3):236-8.

21. Mendoza T, García de los Ríos M, Lafourcade M, Soto C, Durruty P, Alvo M. Asymptomatic bacteriuria in type 2 diabetics women. Rev Med Chil; 2002;130(9):1001-7.

22. Makuyana D, Mhlabi D, Chipfupa M, Munyombwe T, Gwanzura L. Frequency, risk factors, and responsible pathogenic microorganisms of asymptomatic bacteriuria in patients with type 2 diabetes mellitus in an urban black population. Cent Afr J Med. 2002;48(7-8):78-82.

23. Cantagallo A, Delci Castelli M. Cost-free prevention to asymptomatic bacteriuria in diabetic women: two hands, two towels. Diabetes Care. 2001;24(2):412-4.
24. Hermida Pérez JA, Vento Remedios TE, Pérez Fernández L, Acosta Lorenzo JA, Acosta Bernad I, Calvo Azparren E, et al. Asymptomatic bacteriuria or "detected" bacteriuria in the female. Incidence in our health area Arch Esp Urol. 1998;51(2):145-9.

25. Balasoiu D, van Kessel KC, van Kats-Renaud HJ, Collet TJ, Hoepelman AI. Granulocyte function in women with diabetes and asymptomatic bacteriuria. Diabetes Care. 1997;20(3):392-5.

26. Kayima JK, Otieno LS, Twahir A, Njenga E. Asymptomatic bacteriuria among diabetics attending Kenyatta National Hospital. East Afr Med J. 1996;73(8):524-6.

27. Keane EM, Boyko EJ, Reller LB, Hamman RF. Prevalence of asymptomatic bacteriuria in subjects with NIDDM in San Luis Valley of Colorado. Diabetes Care. 1988;11(9):708-12.

28. Abu-Bakare A, Oyaide SM. Asymptomatic bacteriuria in Nigerian diabetics. Trop Med Hyg. 1986;89(1):29-32.

29. Schmitt JK, Fawcett CJ, Gullickson G. Asymptomatic bacteriuria and hemoglobin A1. Diabetes Care. 1986;9(5):518-20.

30. Nicolle LE, Bradley S, Colgan R, et al. Infectious diseases society of America guidelines for the diagnosis and treatment of symptomatic bacteriuria in adults. Clin Infect Dis. 2005;40:643-54.

31. Geerlings SE, Stolk RP, Bravenboer RP, Collet JT, Jansz, et al. ASB may be considered a complication in women with diabetes. Diabetes mellitus women ASB Utrecht study group. Diabetes Care. 2000;23:744-749.

32. Alebiosu CO, Osinupebi OA, Olajubu FA. Significant asymptomatic bacteriuria among Nigerian type 2 diabetics. J Natl Med Assoc. 2003;95(5):349-50.

33. Hansen DS, Gottschau A, Kolmos HJ. Epidemiology of Klebsiella bacteraemia: A case control study using Escherichia coli bacteraemia as control. J Hosp Infect. 1998;38(2):119-32.

34. Stapleton A. Urinary tract infections in patients with diabetes. Am J Med. 2002;113:80-84.

35. Suzanne E, Geerlings, Ellen C, Brouwer, Wim Gaastra, Ronald Stolk, Rob JA, et al. Virulence factors of Escherichia coli isolated from urine of diabetic women with asymptomatic bacteriuria: Correlation with clinical characteristics. Antonie van Leeuwenhoek. 2001;80:119-127.

36. Mizunoe Y, Matsumoto T, Sakimoto M, Kubo S, Mochida O, Sakamoto Y, et al. Renal scarring by mannose-sensitive adhesin of Escherichia coli type 1 pili. Nephron. 1997;77:412-416.

37. Kasiyan GR, Berketova Tiu, Sarkisian AZ, Rubanov VA. Methods of diagnosis and treatment of asymptomatic bacteriuria in postmenopausal women suffering from type 2 diabetes mellitus. Urologiia. 2012; (1):16-20.

38. Dalal S, Nicolle L, Marrs CF, Zhang L, Harding G, Foxman B. Long-term Escherichia coli asymptomatic bacteriuria among women with diabetes mellitus. Clin Infect Dis. 2009;49(4):491-7.

39. Ribera MC, Pascual R, Orozco D, Pérez Barca C, Pedrera V, Gil V. Incidence and risk factors associated with urinary tract infection in diabetic patients with and without asymptomatic bacteriuria. Eur J Clin Microbiol Infect Dis. 2006;25:389-93.

40. Meiland R, Geerlings SE, Stolk RP, Hoes AW, Hoepelman AI. History taking and leukocyturia predict the presence of asymptomatic bacteriuria in women with diabetes mellitus. Eur J Epidemiol. 2004;19(11):1021-7.

41. Boyko EJ, Fihn SD, Scholes D, Abraham L, Monsey B. Risk of urinary tract infection and asymptomatic bacteriuria among diabetic and nondiabetic postmenopausal women. Am J Epidemiol. 2005;161(6):557-64.

42. Nicolle LE, Zhanel GG, Harding GK. Microbiological outcomes in women with diabetes and untreated asymptomatic bacteriuria. World J Urol. 2006;24(1):61-5.

43. Harding GK, Zhanel GG, Nicolle LE, Cheang. Antimicrobial treatment in diabetic women with asymptomatic bacteriuria. Manitoba Diabetes Urinary Tract Infection Study Group. N Engl J Med. 2002;347(20):1576-83.

44. Geerlings SE, Stolk RP, Camps MJ, Netten PM, Collet JT, Schneeberger PM, et al. Consequences of asymptomatic bacteriuria in women with diabetes mellitus. Arch Intern Med. 2001;161(11):1421-7.

45. Zhanel GG, Nicolle LE, Harding GK. Prevalence of asymptomatic bacteriuria and associated host factors in women with diabetes mellitus. The Manitoba
46. Colgan R, Nicolle LE, McGlone A, Hooton TM. Asymptomatic bacteriuria in adults. Am Fam Physician. 2006;74(6):985-90.

47. Stein G, Fünfstück R. Asymptomatic bacteriuria. Med Klin (Munich). 2000;95(4):195-200.

48. Marschall J, Piccirillo ML, Foxman B, Zhang L, Warren DK, Henderson JP; CDC Prevention Epicenters Program. Patient characteristics but not virulence factors discriminate between asymptomatic and symptomatic *E. coli* bacteriuria in the hospital. BMC Infect Dis. 2013;13:213.

49. Schneeberger C, Kazemier BM, Geerlings SE. Asymptomatic bacteriuria and urinary tract infections in special patient groups: women with diabetes mellitus and pregnant women. Curr Opin Infect Dis. 2014;1(1):108-14.

50. Nakano H, Oba K, Saito Y, Ouchi M, Yamashita N, Okamura K, et al. Asymptomatic pyuria in diabetic women. J Nippon Med Sch. 2001;68(5):405-10.

51. Papazafiropoulou A, Daniil I, Sotiropoulos A, Balampani E, Kokolaki A, Bousboulas S, et al. Prevalence of asymptomatic bacteriuria in type 2 diabetic subjects with and without microalbuminuria. BMC Res Notes. 2010;3:169.

52. Aswani SM, Chandrashekar U, Shivashankara K, Pruthvi B. Clinical profile of urinary tract infections in diabetics and non-diabetics. Australas Med J. 2014;7(1):29-34.

53. Nicolle LE. Asymptomatic bacteriuria in diabetic women. Diabetes Care. 2000;23:722-723.

54. Chernew I, Braude AI. Depression of phagocytosis by solutes in concentrations found in the kidney and urine. J Clin Invest. 1962;10:1945-1953.

55. Nicolle LE. Asymptomatic bacteriuria: review and discussion of the IDSA guidelines. Int J Antimicrob Agents. 2006;1:S42-8.

56. Burekovic A, Dizdarevic-Bostandzic A, Godinjak A. Poorly regulated blood glucose in diabetic patients-predictor of acute infections. Med Arch. 2014;68(3):163-6.

57. Raz R, Stamm WE. A controlled trial of intravaginal esterol in postmenopausal women with recurrent urinary tract infection. N Eng J Med. 1993;329:753-756.

58. Botto H, Neuzillet Y. Effectiveness of a cranberry (*Vaccinium macrocarpon*) preparation in reducing asymptomatic bacteriuria in patients with an ileal enterocystoplasty. Scand J Urol Nephrol. 2010;44:165–8.

© 2016 Deraje et al.; This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

---

Peer-review history:

The peer review history for this paper can be accessed here:

http://sciencedomain.org/review-history/11497